Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT01608074

Radical Fimbriectomy for Young BRCA Mutation Carriers

Radical Fimbriectomy for Young BRCA Mutation Carriers at Risk of Pelvic Serous Carcinoma

Status
Active Not Recruiting
Phase
N/A
Study type
Interventional
Enrollment
123 (actual)
Sponsor
Centre Oscar Lambret · Academic / Other
Sex
Female
Age
35 Years
Healthy volunteers
Not accepted

Summary

Some BRCA-mutated women are reluctant to undergo laparoscopic bilateral salpingo-oophorectomy. The goal of the bilateral laparoscopic radical fimbriectomy the investigators suggest, is to suppress the tubal source of possible dysplastic cells from which can stem this high grade tumor, while preserving a natural ovarian hormonal secretion.

Detailed description

Most of ovarian carcinomas related to BRCA 1 or 2 mutations are of fallopian tube origin and especially from its distant part called the fimbria. These tubal, ovarian or primary peritoneal carcinomas are quite always of high grade serous type. They cannot be effectively screened due to the quickness of their evolution. In this context, a laparoscopic bilateral salpingo-oophorectomy (BSO) is the recommended prophylactic procedure. Some BRCA-mutated women are reluctant to undergo this procedure considering the numerous adverse effects on body and quality of life, especially when hormonal replacement is forbidden. This refusal makes them at risk of developing a serous pelvic carcinoma. The goal of the bilateral laparoscopic radical fimbriectomy the investigators suggest, is to suppress the tubal source of possible dysplastic cells from which can stem this high grade tumor, while preserving a natural ovarian hormonal secretion

Conditions

Interventions

TypeNameDescription
PROCEDURERadical fimbriectomyLaparoscopic bilateral radical fimbriectomy : Complete resection of the tubes, from the uterine tube (up against the uterus) to the fimbriae, with resection of the part of the ovary adjacent to the ovarian fimbriae (adhering to the ovary)
OTHERHistopathology SEE-FIMAnatomopathological study of surgical specimens

Timeline

Start date
2012-01-09
Primary completion
2033-08-01
Completion
2033-08-01
First posted
2012-05-30
Last updated
2026-03-18

Locations

14 sites across 1 country: France

Source: ClinicalTrials.gov record NCT01608074. Inclusion in this directory is not an endorsement.